CAR-T细胞治疗肿瘤的脱靶效应及其预防策略

发布时间：2018-05-01 15:43

  本文选题：嵌合抗原受体 + 肿瘤免疫治疗　； 参考：《中国肿瘤生物治疗杂志》2017年03期

【摘要】：嵌合抗原受体(chimeric antigen receptor,CAR)是单链抗体的可变区(single-chain variable fragments,scFv)和T细胞信号分子的重组融合蛋白,它使T细胞可以通过非MHC限制性方式识别特异性抗原。最近的临床研究证明,CAR-T细胞在治疗B细胞肿瘤中取得了显著效果。但在目前的临床应用中存在诸多限制,尤其是当肿瘤抗原在正常组织中表达时会造成脱靶效应。本文就靶抗原的选择、脱靶效应及相应的预防策略作一综述,期望这些策略的实施,将会提高CAR-T细胞治疗的安全性及有效性,使更多肿瘤患者从中获益。
[Abstract]:Chimeric antigen receptor carr) is a variable region single-chain variable fragments scFv) and a recombinant fusion protein of T cell signaling molecules, which enables T cells to recognize specific antigens by non-MHC restriction. Recent clinical studies have demonstrated that CAR-T cells are effective in the treatment of B-cell tumors. However, there are many limitations in clinical application, especially when tumor antigens are expressed in normal tissues. In this paper, the selection of target antigen, miss effect and corresponding preventive strategies are reviewed. It is hoped that the implementation of these strategies will improve the safety and effectiveness of CAR-T cell therapy and benefit more cancer patients.
【作者单位】： 河北医科大学第四医院肿瘤科;
【分类号】：R730.51
，

本文编号：1830052